Results 261 to 270 of about 5,115,827 (299)

Integrated continuous production of recombinant therapeutic proteins

Biotechnology and Bioengineering, 2012
AbstractIn the current environment of diverse product pipelines, rapidly fluctuating market demands and growing competition from biosimilars, biotechnology companies are increasingly driven to develop innovative solutions for highly flexible and cost‐effective manufacturing.
Veena, Warikoo, Rahul, Godawat, Kevin, Brower, Sujit, Jain, Daniel, Cummings, Elizabeth, Simons, Timothy, Johnson, Jason, Walther, Marcella, Yu, Benjamin, Wright, Jean, McLarty, Kenneth P, Karey, Chris, Hwang, Weichang, Zhou, Frank, Riske, Konstantin, Konstantinov   +15 more
openaire   +2 more sources

Sustainability by design for recombinant protein therapeutics

Drug Discovery Today
Recombinant protein therapeutics play a vital role in pharmacology, offering precise and effective treatments. However, their development faces sustainability challenges, including high attrition rates, resource-intensive processes, and complex supply chains, leading to waste, emissions, and high costs.
Renato Mastrangeli, Maria Concetta Audino, Steve Marquis Fernandes, Horst Bierau   +3 more
openaire   +2 more sources

GlycoFi's technology to control the glycosylation of recombinant therapeutic proteins

Expert Opinion on Drug Discovery, 2009
Therapeutic properties of many glycoproteins strongly depend on the composition of their glycans. Most of the current approved glycoproteins are produced in mammalian cell lines, which yield mixture of different glycoforms close to the human one but not fully identical.
Alain, Beck, Olivier, Cochet, Thierry, Wurch   +2 more
openaire   +2 more sources

Structural Characterization of Recombinant Therapeutic Proteins by Circular Dichroism

Current Pharmaceutical Biotechnology, 2011
Most of the protein therapeutics are now produced by recombinant DNA technology. The advantages of recombinant proteins are related to their higher specificity and to their safety as exposure to animal or human diseases. However, several problems are still present in development of recombinant proteins as therapeutics, such as low bioavailability ...
BERTUCCI, CARLO, PISTOLOZZI, MARCO, DE SIMONE, ANGELA   +2 more
openaire   +4 more sources

Applications of capillary electrophoresis in characterizing recombinant protein therapeutics

ELECTROPHORESIS, 2013
The use of recombinant protein for therapeutic applications has increased significantly in the last three decades. The heterogeneity of these proteins, often caused by the complex biosynthesis pathways and the subsequent PTMs, poses a challenge for drug characterization to ensure its safety, quality, integrity, and efficacy.
Shuai Sherry, Zhao, David D Y, Chen
openaire   +2 more sources

Factors that contribute to the immmunogenicity of therapeutic recombinant human proteins

Thrombosis and Haemostasis, 2008
SummaryUse of recombinant human proteins has revolutionized medicine by providing over 200 highly purified hormones and proteins that effectively treat many inherited and acquired peptide hormone and protein deficiencies. With the exception of therapeutic monoclonal antibodies, these biological medicines are synthesized by cultured cells using DNA ...
Ilya, Mukovozov, Thomas, Sabljic, Gonzalo, Hortelano, Frederick A, Ofosu   +3 more
openaire   +2 more sources

Recombinant therapeutic proteins: Production platforms and challenges

Biotechnology Journal, 2008
AbstractSince the approval of insulin in 1982, more than 120 recombinant drug substances have been approved and become available as extremely valuable therapeutic options. Exact copying of the most common human form is no longer a value per se, as challenges, primarily related to the pharmacokinetics of artificial recombinant drugs, can be overcome by ...
openaire   +2 more sources

Therapeutic Use of Recombinant Proteins

1999
Cytokines are soluble proteins with diverse biologic and regulatory actions, which are produced by various cell types, including mononuclear cells of the immune system. These proteins act as hormones and can have their effects at sites distant from the point of secretion.
openaire   +1 more source

Strategies for Modulation of Pharmacokinetics of Recombinant Therapeutic Proteins

Biology Bulletin Reviews, 2018
The review describes current approaches to the optimization of pharmacokinetic properties of pharmaceutical proteins in order to achieve the maximum therapeutic effect. Examples of such technologies, including PEGylation, PEG mimetics, glycosylation, protein–protein fusion, and their advantages and limitations are discussed.
E. A. Zvonova, A. A. Tyurin, A. A. Soloviev, I. V. Goldenkova-Pavlova   +3 more
openaire   +1 more source

Potential therapeutic recombinant proteins comprised of peptides containing recombined T cell epitopes

Molecular Immunology, 1994
The complete primary structure of Fel d I2 has been determined and shown to be comprised of two separate polypeptide chains (designated chain 1 and 2). Overlapping peptides covering the entire sequence of both chains of Fel d I have been used to map the major areas of human T cell reactivity.
Bruce L. Rogers, Julian F. Bond, Sandra J. Craig, Anneliese K. Nault, Debra B. Segal, Jay P. Morgenstern, Chen Meei-Song, Christine B. Bizinkauskas, Catherine M. Counsell, Annette M. Lussier, Thomas Luby, Kuo Mei-Chang, Thomas J. Briner, Richard D. Garman   +13 more
openaire   +2 more sources